230 related articles for article (PubMed ID: 37731723)
21. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness.
Ncube BM; Dube A; Ward K
J Pharm Policy Pract; 2021 Mar; 14(1):29. PubMed ID: 33685518
[TBL] [Abstract][Full Text] [Related]
22. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation.
Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK
BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720
[TBL] [Abstract][Full Text] [Related]
23. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
[TBL] [Abstract][Full Text] [Related]
24. The process of ratifying the treaty to establish the African Medicines Agency: perspectives of national regulatory agencies.
Ncube BM; Dube A; Ward K
Health Policy Plan; 2024 May; 39(5):447-456. PubMed ID: 38497780
[TBL] [Abstract][Full Text] [Related]
25. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
26. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
27. Situation analysis on the regulation of nanomedicines in Southern Africa.
Mudyiwenyama LG; Khoza S; Dube A
Front Med (Lausanne); 2023; 10():1098830. PubMed ID: 37153083
[TBL] [Abstract][Full Text] [Related]
28. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?
Vaz A; Roldão Santos M; Gwaza L; Mezquita González E; Pajewska Lewandowska M; Azatyan S; Saint-Raymond A
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):11-17. PubMed ID: 35130803
[TBL] [Abstract][Full Text] [Related]
29. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
[TBL] [Abstract][Full Text] [Related]
30. Will the EU Clinical Trials Regulation Support the Innovative Industry in Bringing New Medicines Faster to Patients?
Atzor S; Gokhale S; Doherty M
Pharmaceut Med; 2013 Apr; 27(2):75-82. PubMed ID: 23585715
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.
McAuslane N; Bujar M; Sithole T; Ngum N; Owusu-Asante M; Walker S
Pharmaceut Med; 2023 May; 37(3):251-260. PubMed ID: 37074548
[TBL] [Abstract][Full Text] [Related]
32. The domestication of the African Union model law on medical products regulation: Perceived benefits, enabling factors, and challenges.
Ncube BM; Dube A; Ward K
Front Med (Lausanne); 2023; 10():1117439. PubMed ID: 36793874
[TBL] [Abstract][Full Text] [Related]
33. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
34. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
[TBL] [Abstract][Full Text] [Related]
35. Assessment of pharmacovigilance guidelines in the Southern African Development Community: A document review.
Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR
Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5755. PubMed ID: 38362654
[TBL] [Abstract][Full Text] [Related]
36. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
37. Institutionalization of African traditional medicine in health care systems in Africa.
Kofi-Tsekpo M
Afr J Health Sci; 2004; 11(1-2):i-ii. PubMed ID: 17298111
[TBL] [Abstract][Full Text] [Related]
38. Medicines Regulation in Africa: Current State and Opportunities.
Ndomondo-Sigonda M; Miot J; Naidoo S; Dodoo A; Kaale E
Pharmaceut Med; 2017; 31(6):383-397. PubMed ID: 29200865
[TBL] [Abstract][Full Text] [Related]
39. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.
Sillo HB; Masota NE; Kisoma S; Rago L; Mgoyela V; Kaale EA
PLoS One; 2018; 13(5):e0197490. PubMed ID: 29787579
[TBL] [Abstract][Full Text] [Related]
40. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
